Publications by authors named "Caroline Clairmont"
Purpose: VNP40101M is a new alkylating agent that demonstrated broad anti-tumor activity in murine tumor models. A phase I trial was initiated to determine the toxicities, maximum tolerated dose, and pharmacokinetics of VNP40101M by short IV infusion.
Study Design: The starting dose was 3 mg/m(2) every four weeks, and was escalated in successive cohorts as follows: 6, 12, 24, 40, 60, 80, and 100 mg/m(2).
Purpose: 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a new and potent inhibitor of ribonucleotide reductase (RR), increases the cellular uptake, DNA incorporation, and cytotoxicity of gemcitabine in tumor cell lines. A phase I trial was initiated to determine the safety profile and maximum tolerated doses of 3-AP and gemcitabine when used in combination in patients with advanced cancer.
Study Design: 3-AP and gemcitabine were administered on days 1, 8, and 15 of each 28-day cycle.
Purpose: VNP40101M is a novel sulfonylhydrazine alkylating agent with broad antitumor activity in animal models. As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS).
Experimental Design: VNP40101M was given as a single i.
Article Synopsis
- 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is being tested in a phase I trial to determine its dose-limiting toxicities, maximum-tolerated dose, and pharmacokinetics for patients with advanced cancer via a 96-hour IV infusion.
- During the trial, 21 patients were enrolled, with some experiencing dose-limiting toxicities like neutropenia and nausea at higher doses, leading to the determination of a recommended dose of 120 mg/m²/d every 2 weeks.
- Although there were no objective responses to treatment, some patients showed disease stabilization and decreases in tumor markers, indicating the need for further phase II trials.
Article Synopsis
- A Phase I study was conducted to evaluate the safety, pharmacokinetics, and maximum tolerated dose of Triapine, a ribonucleotide reductase inhibitor, in patients with advanced cancer.
- Triapine was given through a daily 2-hour infusion for 5 days, with dose adjustments made due to adverse events and a modified escalation scheme implemented.
- The trial involved 32 patients, revealing that the primary toxic effects included grade 3-4 leukopenia and various grade 1-2 nonhematological side effects, with significant hematological toxicity observed at higher doses.
We performed a pilot trial in refractory cancer patients to investigate the feasibility of intratumoral injection of TAPET-CD, an attenuated Salmonella bacterium expressing the E. coli cytosine deaminase gene. A total of three patients received three dose levels of TAPET-CD (3 x 10(6)-3 x 10(7) CFU/m(2)) via intratumoral injection once every 28 days as long as progression of disease or intolerable toxicity was not observed.
View Article and Find Full Text PDF